Vilon Research: Dipeptide Thymic Bioregulator

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator derived from the thymus gland, developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. As the smallest compound in the Khavinson bioregulator series at just two amino acids (MW 275 Da), Vilon represents the minimal thymic-derived sequence with documented immunomodulatory activity in published research models.

Structural Simplicity and Research Significance

The dipeptide Lys-Glu contains just two residues — a lysine with its positively charged epsilon-amine at physiological pH, and a glutamate with its negatively charged gamma-carboxylate. This ionic complementarity between the two residues enables salt bridge formation that stabilises a compact conformation, and the overall near-neutral net charge at pH 7.4 (Lys +1, Glu -1 = 0) provides reasonable aqueous solubility without the charge-dependent precipitation issues that affect many synthetic peptides.

Vilon's simplicity has important research advantages. As a dipeptide, it can be chemically characterised and confirmed by multiple standard analytical methods — mass spectrometry, NMR, HPLC — with high confidence in structural identity. It has no stereochemical ambiguity in backbone geometry (both residues are L-configuration). And its small size means that essentially all of the molecule is pharmacophore — there are no conformationally flexible linker regions or terminal extensions that complicate structure-activity analysis.

Thymic Biology Context

Vilon was developed in the context of thymic involution research — the age-related progressive loss of thymic cortex and medulla that produces dramatically reduced naive T cell output by the fifth decade of life. The thymus is the exclusive site of T lymphocyte maturation from haematopoietic progenitors, and its involution produces the adaptive immune contraction characteristic of immunosenescence.

The thymulin bioassay provides the primary functional endpoint for thymic epithelial biology research relevant to Vilon. Thymulin (Facteur Thymique Sérique) is a zinc-requiring nonapeptide hormone produced exclusively by thymic epithelial cells. Its plasma concentration declines with age in parallel with thymic involution, and it is proposed to drive T cell maturation in the thymic cortex. Measuring thymulin production by thymic epithelial cell cultures treated with Vilon provides direct insight into bioregulator effects on thymic endocrine function.

Immunological Research Applications

T cell proliferation in aged models: Splenocytes from aged rodents (18-24 months) show measurably reduced proliferative responses to T cell mitogens compared to young adults (2-4 months) — reflecting the reduced naive T cell pool and altered T cell subset composition that accompanies immunosenescence. Vilon treatment (1nM-100µM range, testing broad concentration range for dipeptides) of aged splenocyte cultures before mitogenic stimulation (concanavalin A 2.5µg/mL or anti-CD3/CD28 antibodies) allows assessment of proliferative restoration. Measure by [3H]-thymidine incorporation (last 18 hours of 72-hour culture) or CFSE dilution by flow cytometry.

Cytokine profiling: Measure IL-2 (24 hours, the primary autocrine T cell proliferation cytokine), IL-4 and IL-13 (Th2 markers), IFN-gamma (Th1 marker), and IL-17 (Th17 marker) in supernatants from Vilon-treated stimulated T cell cultures. The Th1/Th2/Th17 balance provides mechanistic insight into whether Vilon preferentially supports specific T cell subset responses.

NK cell function: Natural killer cell cytotoxicity against K562 targets (which lack MHC I and are therefore sensitive to NK killing) provides a GHS-independent innate immune endpoint. Enrich NK cells from splenocyte preparations by negative selection. Pre-treat with Vilon for 24 hours. Perform 4-hour 51Cr release assay at multiple effector:target ratios.

Comparative Bioregulator Research

The most informative Vilon research design places it within the context of the full thymic bioregulator series. Running Vilon (dipeptide, 275 Da), Thymalin (polypeptide, 1400-1500 Da), and Thymosin Alpha-1 (defined 28 amino acid peptide, 3108 Da) in parallel immunological assays at matched mass concentrations (µg/mL) and separately at matched molar concentrations (nM) provides complementary information. Mass-matched comparison reflects clinical dosing conventions; molar-matched comparison reflects receptor pharmacology conventions. The two comparisons together characterise whether potency differences are attributable to molecular weight or to intrinsic activity at the relevant receptors.

Key Published Research

• Morozov VG, Khavinson VKh. "Natural and synthetic thymic peptides as therapeutics for immune dysfunction." International Journal of Immunopharmacology, 1997. PMID: 9088759
• Khavinson VK, et al. "Peptide regulation of ageing." St. Petersburg: Humanistics, 2003.
• Anisimov SV, et al. "Effect of the synthetic thymic dipeptide Vilon and melatonin on gene expression in lymphocytes of old mice." Advances in Gerontology, 2004.

View Vilon →

For laboratory and analytical research purposes only. Not for human or veterinary use.

Vilon and Longevity Research

Khavinson's bioregulator research programme has examined lifespan effects of repeated administration in rodent models. Published research from the Saint Petersburg Institute examined the combination of thymic and pineal bioregulators — Vilon (thymus) alongside Epithalon (pineal) — in aged mice and rats. The combination approach reflects the multisystem nature of ageing and the hypothesis that thymic immune restoration and pineal circadian/antioxidant normalisation are complementary targets.

For ageing research design with Vilon: aged C57BL/6 mice (18 months, equivalent to approximately 60 human years) treated with Vilon (intraperitoneal or subcutaneous, daily for 10 days per month) over a 6-month period. At study endpoint, measure: immune function (NK cytotoxicity, T cell proliferative responses, thymulin plasma levels); oxidative stress markers (plasma TBARS, SOD activity, catalase activity); tumour incidence (gross necropsy); and if lifespan extension is the endpoint, Kaplan-Meier survival analysis.

In vitro surrogate endpoints for longevity research: telomere length (by quantitative FISH or qPCR-based relative telomere measurement) in peripheral blood lymphocytes and fibroblasts before and after Vilon treatment; SA-beta-galactosidase positive cells as a senescence marker; and p21/p16 expression by Western blot as senescence-associated growth arrest markers.

Vilon as a Minimal Pharmacophore Reference

Vilon (Lys-Glu) is the minimal dipeptide in the thymic bioregulator series. Using it as a minimal pharmacophore reference, researchers can build upward in complexity: Lys-Glu (Vilon, 2 residues) → Thr-Lys-Pro-Arg (Tuftsin, 4 residues, parent compound of Selank) → Lys-Pro-Val (KPV, C-terminal alpha-MSH tripeptide) → Thymosin Alpha-1 (28 residues). This structural ladder from dipeptide to 28-mer, all with immunomodulatory properties, provides a systematic framework for identifying the minimum effective pharmacophore for specific immune endpoints. Testing all four compounds in parallel at matched molar concentrations in the same NK cell cytotoxicity or T cell proliferation assay maps the relationship between molecular complexity and immunological activity — fundamental structure-activity data for the thymic peptide field.

Vilon and T Cell Receptor Signalling Research

The mechanistic basis for Vilon's proposed T cell immunostimulatory effects — if receptor-mediated rather than purely epigenetic — may involve modulation of T cell receptor (TCR) signalling thresholds. Published research on thymic peptide effects on T cell activation has proposed that thymulin and related thymic factors lower the activation threshold for TCR-mediated signalling in mature peripheral T cells, making them more responsive to sub-threshold antigen concentrations.

For TCR signalling threshold research: use Jurkat T cell line (a well-characterised T cell signalling model) transfected with an NFAT-luciferase reporter (nuclear factor of activated T cells drives luciferase expression upon TCR activation). Stimulate with anti-CD3 antibody at concentrations spanning the TCR activation threshold (0.01-1µg/mL plate-bound anti-CD3) with and without Vilon pre-treatment (1nM-100µM, 24 hours). Measure luciferase activity at 6 hours after stimulation. A leftward shift in the anti-CD3 dose-response curve in Vilon-treated cells (lower EC50 for NFAT activation) would indicate reduced TCR activation threshold — a direct molecular mechanism for enhanced T cell responsiveness.

Downstream from TCR activation: measure CD69 expression (early T cell activation marker) by flow cytometry at 6 hours; CD25 (IL-2 receptor alpha chain, marks sustained activation) at 24 hours; and IL-2 secretion (primary T cell autocrine growth factor) by ELISA at 24 hours following sub-threshold anti-CD3 stimulation. Vilon effects at sub-threshold (but not supra-threshold) anti-CD3 concentrations would be consistent with a threshold-lowering rather than non-specific T cell activation mechanism.

Vilon and Oxidative Stress in Immune Cells

Aged immune cells show elevated oxidative stress — accumulated mitochondrial ROS, reduced GSH/GSSG ratio, and elevated protein carbonylation — that impairs T cell function independently of thymic involution effects. Published research has examined antioxidant properties of thymic bioregulators in aged lymphocyte models.

For oxidative stress in aged T cell research: isolate PBMCs from elderly donors (65+ years). Measure intracellular ROS by CM-H2DCFDA fluorescence (flow cytometry) in CD3+ T cells gated from the PBMC preparation. Measure GSH by ThiolTracker Violet in the same gate. Treat with Vilon (1nM-100µM, 48 hours) and re-measure ROS and GSH. Compare with N-acetylcysteine (NAC, 1mM) as a positive control for antioxidant-mediated T cell restoration. If Vilon reduces intracellular ROS and restores GSH in aged T cells, and if this correlates with improved proliferative responses to ConA stimulation, this establishes a mechanistic link between Vilon's antioxidant properties and its immunostimulatory effects — potentially more relevant than a direct epigenetic mechanism for peripheral T cell biology.

Vilon's role in the thymic bioregulator research series extends to questions of minimum effective molecular size for epigenetic regulation. The Khavinson group's published chromatin interaction studies using short peptides (2-7 residues) across multiple tissue-derived bioregulators have proposed that as few as 2-3 amino acids can produce sequence-specific chromatin effects — a hypothesis that challenges conventional understanding of epigenetic regulation but is consistent with structural data showing that short charged peptides can occupy the major groove of DNA and influence transcription factor binding. For researchers interested in this mechanism, Vilon (Lys-Glu) provides the smallest possible research tool — a dipeptide test of the minimum pharmacophore hypothesis. Parallel experiments with Lys alone, Glu alone, and the combined Lys-Glu dipeptide can directly test whether the biological activity requires both residues together, or whether single amino acid effects account for the observed immunomodulation.